Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Unraveling the logic of genes with Boolean network models

Over the last 20 years, researchers in biology and medicine have created Boolean network models to simulate complex systems and find solutions, including new treatments

January 23, 2024

Gilead urged to improve access to HIV drug by public figures and celebrities – Pharmaceutical Technology

Gilead Sciences headquarters in Silicon Valley. Gilead’s HIV drug Sunlenca (lenacapavir) gained FDA approval in 2022. Credit: Sundry Photography via Shutterstock. Public figures, scientists, medical

May 30, 2024

Leading health issues affecting older adults before the 2024 elections

Researchers surveyed adults aged ≥50 years to identify the most salient health concerns before the 2024 elections in the United States.

August 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.